Overview

ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere

Status:
Unknown status
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
The purposes of this study are to determine if DN-101 plus Taxotere lowers PSA levels, delays or limits disease progression and is safe with minimal side effects.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Novacea
Collaborator:
Aventis Pharmaceuticals
Treatments:
Androgens
Calcitriol
Docetaxel